Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 
 

New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer

  • The multidisciplinary Oncology Partnership and Education Network (OPEN) aims to improve patient outcomes in oncology, with initial focus on metastatic colorectal cancer (mCRC)
  • OPEN aims to raise public awareness and understanding of the importance of biomarker testing in mCRC
 

Metastatic colorectal cancer (mCRC)

EMD Serono announced the formation of the global Oncology Partnership and Education Network (OPEN). This global initiative, supported by EMD Serono, brings together a multidisciplinary group of stakeholders involved with the management of cancer to help improve patient care. Focusing on metastatic colorectal cancer (mCRC) as its first priority, OPEN aims to reinforce the important role biomarker testing has in personalizing care in mCRC.

Additional information

RAS BIOMARKER TESTING EXPLAINED

RAS Biomarker Testing Explained
Watch this video to learn more about RAS biomarker testing and its value for people newly diagnosed with metastatic colorectal cancer.

ROLE OF RAS BIOMARKER TESTING IN MCRC

Role of RAS Biomarker Testing in Metastatic Colorectal Cancer Care
Learn more about the steps taken by doctors to select an appropriate treatment for a person newly diagnosed with metastatic colorectal cancer.

ROLE OF RAS GENES AND BIOMARKERS IN MCRC

Role of RAS
Watch this video to learn about the role of RAS genes and the relevance of RAS genetic status for people newly diagnosed with metastatic colorectal cancer.

GLOBAL CANCER NEWS

Global Cancer News
Access the latest information developed for global media on EMD Serono Oncology products, and respective disease areas, including expert videos and fact sheets.

MCRCBIOMARKERS .COM

mCRCBiomarkers .com
Learn more about the RAS biomarker testing from leading experts and published literature, and the importance of identifying RAS tumor status in metastatic colorectal cancer patients.

FACT SHEETS

Additional Information
Background information on RAS biomarker testing and metastatic colorectal cancer.

CONTACT

Gangolf Schrimpf
Gangolf Schrimpf
Tel: +49 6151 72 9591
Fax: +49 6151 72-919591
E-Mail

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 
Merck KGaA, Darmstadt, Germany on Facebook
Twitter